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manifestations: a cross-sectional study
Elisabeth APM Romme1,2*, David A McAllister3, John T Murchison4, Edwin JR Van Beek5, George S Petrides6,
Cameron OS Price4, Erica PA Rutten7, Frank WJM Smeenk1, Emiel FM Wouters2 and William MacNee8Abstract
Background: Cardiovascular disease, osteoporosis and emphysema are associated with COPD. Associations
between these factors and whether they predict all-cause mortality in COPD patients are not well understood.
Therefore, we examined associations between markers of cardiovascular disease (coronary artery calcification [CAC],
thoracic aortic calcification [TAC] and arterial stiffness), bone density (bone attenuation of the thoracic vertebrae),
emphysema (PI-950 and 15th percentile) and all-cause mortality in a COPD cohort.
Methods: We assessed CAC, TAC, bone attenuation of the thoracic vertebrae, PI-950 and 15th percentile on
low-dose chest computed tomography in COPD subjects. We measured arterial stiffness as carotid-radial pulse wave
velocity (PWV), and identified deaths from the national register.
Results: We studied 119 COPD subjects; aged 67.8 ±7.3, 66% were males and mean FEV1% predicted was
46.0 ±17.5. Subjects were classified into three pre-specificed groups: CAC = 0 (n = 14), 0 < CAC ≤ 400 (n = 41) and
CAC > 400 (n = 64). Subjects with higher CAC were more likely to be older (p < 0.001) and male (p = 0.03), and more
likely to have higher systolic blood pressure (p = 0.001) and a history of hypertension (p = 0.002) or ischemic heart
disease (p = 0.003). Higher CAC was associated with higher PWV (OR 1.62, p = 0.04) and lower bone attenuation
(OR 0.32, p = 0.02), but not with 15th percentile, after adjustment for age, sex and pack-years of smoking. In a Cox
proportional hazards model, CAC, TAC and 15th percentile predicted all-cause mortality (HR 2.01, 2.09 and 0.66,
respectively).
Conclusions: Increased CAC was associated with increased arterial stiffness and lower bone density in a COPD
cohort. In addition, CAC, TAC and extent of emphysema predicted all-cause mortality.
Trial registration: Lothian NHS Board, Lothian Research Ethics Committee, LREC/2003/8/28.
Keywords: Arterial calcification, Arterial stiffness, Bone density, Cardiovascular disease, Co-morbidity,
Computed tomography, COPD, Emphysema, Mortality, OsteoporosisBackground
Chronic obstructive pulmonary disease (COPD), in ad-
dition to its pulmonary manifestations, is associated with
significant extrapulmonary manifestations. Cardiovas-
cular disease and osteoporosis are recognised extrapul-
monary manifestations, whose prevalence is higher in
COPD patients than in control subjects matched for age
and sex [1,2].* Correspondence: lisette.romme@catharinaziekenhuis.nl
1Department of Respiratory Medicine, Catharina Hospital, Eindhoven,
The Netherlands
2Department of Respiratory Medicine, Maastricht University Medical Centre +
(MUMC+), P.O. Box 5800, Maastricht 6202 AZ, The Netherlands
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© 2013 Romme et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orIn general population studies, a relationship has been
suggested between cardiovascular disease and osteopo-
rosis. Postmenopausal women with osteoporosis had a
3.9-fold increased risk of cardiovascular events com-
pared with postmenopausal women with osteopenia [3].
In 2348 postmenopausal women, increased aortic calcifi-
cation, a marker of cardiovascular disease, was associa-
ted with lower bone density and an increased number of
vertebral and hip fractures [4], and in a subpopulation
studied longitudinally, progression of aortic calcification
was associated with bone loss [4].
Although cardiovascular disease and osteoporosis are
common in COPD patients [1,2], there are few studiesl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Romme et al. Respiratory Research 2013, 14:129 Page 2 of 7
http://respiratory-research.com/content/14/1/129on the relationship between cardiovascular disease and
osteoporosis in COPD. Sabit and colleagues [5] found
that COPD subjects with osteoporosis had increased ar-
terial stiffness, another marker of cardiovascular disease,
compared with COPD subjects without osteoporosis. In
addition, arterial stiffness and osteoporosis have been
shown to relate to the extent of emphysema [6,7]. These
data suggest associations between cardiovascular disease,
osteoporosis and emphysema. Furthermore, COPD re-
lated extrapulmonary manifestations are thought to con-
tribute to morbidity and mortality [8].
The objectives of this study were: 1. To determine the
associations between markers of cardiovascular disease
(coronary artery calcium [CAC], thoracic aortic calcium
[TAC] and arterial stiffness), bone attenuation of the
thoracic vertebrae, and extent of emphysema, and 2. To
identify whether these factors predict all-cause mortality
in a COPD cohort.
Methods
Our analysis was based on the data of a cohort study
designed to identify prognostic markers in COPD [6].
The study was conducted in accordance with the
amended Declaration of Helsinki, the protocol was
approved by the Lothian Research Ethics Committee
(LREC/2003/8/28), and all subjects gave written in-
formed consent.
Subjects
The inclusion and exclusion criteria have been described
previously [6]. In summary, all subjects were included
between April 2003 and December 2005, had a clinical
history compatible with COPD, a history of smoking for
at least 10 pack-years and evidence of chronic airflow
limitation on spirometry. All subjects who had low-dose
computed tomography (CT) of the chest were included
in our analysis.
Height, weight and post-bronchodilator spirometry
were measured according to American Thoracic Society/
European Respiratory Society standards. The subjects’
self-reported respiratory symptoms, medications, smok-
ing history, occupational exposure, and coexisting me-
dical conditions were documented at study entry using
structured interviews.
Arterial stiffness
Peripheral blood pressure was measured in all subjects,
and arterial stiffness was assessed in 104 subjects. Arter-
ial stiffness was measured as carotid-radial pulse wave
velocity (PWV) as described previously [6]. Briefly, we
used the Q-wave of a simultaneously recorded electro-
cardiograph to identify the onset of the pressure wave,
and used applanation tonometry of the carotid and
radial arteries to record the pressure waveform at theperipheral site. The difference in wave transit time bet-
ween the carotid and radial arteries was used to calculate
carotid-radial PWV.CT scanning
Low-dose CT scanning of the chest was performed with-
out contrast media at full inspiration using a 16-slice
multi-detector-row CT scanner (135 kV, 20 mAS; Toshiba
Aquilion, Toshiba, Japan). Images were reconstructed with
a slice thickness of 1 mm increment using an FC-03 filter
(Toshiba, Japan).
CAC and TAC were assessed on the standard images
used for analysis of the lungs as previously described [9].
Images were analysed on a dedicated post-processing
workstation (VOXAR 3D) using calcium analysis soft-
ware. CAC and TAC were quantified using the Agatston
score [10]. Calcification was defined as an area ≥1 mm2
in the axial plane of a coronary artery or the thoracic
aorta with an attenuation threshold of ≥130 Hounsfield
units. Regions of interest were drawn, and CAC and
TAC were calculated by multiplying by a weighting fac-
tor selected dependent on the peak signal within the re-
gion of interest. Total CAC was obtained by summing
the weighted scores from each coronary artery, and total
TAC was obtained by summing the weighted scores
from the ascending aorta, aortic arch and descending
aorta superiorly to the upper limit of the thoracic verte-
brae 12 (T12). The CT images of a random sample of 25
patients were independently assessed by two observers
and assessed by one observer twice. The intra-class cor-
relation coefficients were high for inter-observer and
intra-observer agreements for CAC (0.88 and 0.99 res-
pectively) and TAC (both 0.99).
Emphysema was quantified by in-house software using
the 15th percentile point of the frequency distribution
of lung attenuation, and pixel index for −950 (PI-950)
Hounsfield units as previously described [6]. Bone at-
tenuation of the thoracic vertebrae was measured ac-
cording to a method described in detail previously [11].
The mean bone attenuation of thoracic vertebrae 4, 7
and 10 (T4, T7 and T10) were determined by placing
circular regions of interest in the central parts of the
vertebral bodies. The average bone attenuation of these
three vertebrae T4, T7 and T10 was calculated and ex-
pressed in Hounsfield units.Mortality
Deaths occurring anywhere in the United Kingdom
were identified by obtaining records from the General
Registry Office for Scotland. Survival time was calcu-
lated in number of days from date of CT scan until
date of death with a census cut-off date of 31 Decem-
ber 2011.
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CAC and TAC were log transformed (normalising/line-
arising transformations). For CAC, subjects were clas-
sified into three pre-specificed groups: CAC = 0, 0 <
CAC ≤ 400 and CAC > 400. Comparisons among the
three groups were made using one way analysis of vari-
ance (ANOVA) or Kruskal-Wallis test. Univariate and
multinominal logistic regression analyses were per-
formed to estimate associations between CAC, TAC,
PWV, bone attenuation and 15th percentile. Time to
death was compared using Kaplan Meier curves, and
Cox proportional-hazards analysis was used to estimate
associations between all-cause mortality and CAC, TAC,
PWV, bone attenuation and 15th percentile.
All statistical analyses were performed in SPSS ver-
sion 17.0 (SPSS Inc., Chicago, IL, USA). Two-sided
p-values ≤0.05 were considered statistically significant.
Results
One hundred nineteen COPD subjects (aged 67.8 ±7.3,
66% were males, mean forced expiratory volume in 1
second [FEV1]% predicted was 46.0 ±17.5) were included
in our analysis. Subjects with higher CAC were more
likely to be older (p < 0.001), male (p = 0.03), and toTable 1 Clinical characteristics of the total cohort and after st
Total cohort CAC =
Number of subjects 119 14
Age, yrs 67.8 ± 7.3 58.6 ± 6
Male, n (%) 79 (66) 7 (50
FEV1, % predicted 46.0 ± 17.5 44.2 ± 1
FVC, % predicted 74.4 ± 20.6 72.6 ± 1
FEV1/FVC ratio 47.1 ± 12.3 46.9 ± 1
BMI, kg/m2 25.8 ± 5.5 25.6 ± 5
Distance walked, m 369.1 ± 112.2 406.6 ± 1
Pack-years of smoking, n 45.4 ± 20.5 44.4 ± 2
Heart rate, beats/min 74.0 ± 13.0 71.5 ± 1
Blood pressure systolic, mmHg 142.2 ± 23.9 127.7 ± 1
Blood pressure diastolic, mmHg 79.9 ± 11.3 76.6 ± 1
Hypertension, n (%) 30 (25) 0 (0)
Ischemic heart disease, n (%) 22 (19) 0 (0)
Diabetes, n (%) 7 (6) 0 (0)
TAC, median (min-max) 1540 (0–20828) 262 (0–4
PWV, m/s 8.90 ± 1.63 8.35 ± 1
PI-950, median in % (min-max) 6.89 (0.12–43.2) 17.1 (0.12–
15th percentile, HU −921.9 ± 27.8 −919.9 ±
Bone attenuation, HU 138.1 ± 35.5 162.2 ± 3
Results are presented as mean ± standard deviation unless otherwise indicated.
PWV was assessed in 104 subjects.
BMI body mass index, CAC coronary artery calcium, FEV1 forced expiratory volume i
PWV pulse wave velocity, TAC thoracic aortic calcium.have higher systolic blood pressure (p = 0.001), a his-
tory of hypertension (p = 0.002) or ischemic heart disease
(p = 0.003), higher TAC (p < 0.001) and lower bone attenu-
ation (p = 0.006) (Table 1). As expected there was a signifi-
cant correlation between CAC and TAC (Spearman’s
r = 0.57, p < 0.001). Higher CAC was associated with
higher PWV (OR 1.62, p = 0.04) and lower bone at-
tenuation (OR 0.32, p = 0.02), but was not associated
with FEV1, 15th percentile and PI-950 after adjustment
for age, sex and pack-years of smoking (Table 2). As de-
scribed previously, PWV correlated with 15th percentile
and PI-950 (r = 0.47, p < 0.001) [6]. Bone attenuation was
not associated with PWV, 15th percentile or PI-950.
Mortality
The median follow-up was 65 (0–83) months. During
the observation period, 30 subjects (25%) died. A re-
spiratory cause of death was the primary aetiology in 18
subjects (60%), and cardiovascular cause of death was
the primary aetiology in 7 subjects (23%). In a Cox
proportional-hazards model, CAC predicted all-cause
mortality after adjustment for age, sex, FEV1 and pack-
years of smoking (HR 2.01, 95% CI 1.13-3.58, p = 0.02,
Table 3). Figure 1 and Table 4 show the Kaplan-Meierratification for CAC
0 0 < CAC≤ 400 CAC > 400 p-value
41 64
.3 66.1 ± 6.2 70.8 ± 6.2 <0.001
) 24 (59) 48 (75) 0.03
3.7 43.8 ± 17.4 47.9 ± 18.3 0.47
4.2 74.4 ± 21.0 74.8 ± 21.7 0.94
0.7 44.9 ± 13.5 48.6 ± 11.9 0.33
.9 25.7 ± 5.2 25.9 ± 5.6 0.98
05.2 385.9 ± 105.0 349.8 ± 116.1 0.16
0.2 44.6 ± 21.7 46.2 ± 20.0 0.91
0.1 73.4 ± 12.0 74.9 ± 14.2 0.65
6.5 136.2 ± 20.3 149.2 ± 25.0 0.001
1.5 78.0 ± 9.2 81.9 ± 12.1 0.11
7 (17) 23 (36) 0.002
4 (10) 18 (28) 0.003
2 (5) 5 (8) 0.25
237) 1125 (3–8606) 3475 (0–20828) <0.001
.36 9.18 ± 1.54 8.86 ± 1.72 0.31
39.0) 5.32 (0.12–43.2) 6.86 (0.27–38.6) 0.81
38.3 −924.2 ± 29.7 −920.8 ± 24.1 0.82
7.6 141.8 ± 31.9 130.4 ± 35.0 0.006
n 1 second, FVC forced vital capacity, HU hounsfield unit, PI pixel index,
Table 2 Multinomial regression for CAC
0 < CAC≤ 400 CAC > 400
Odds ratio 95% CI Odds ratio 95% CI p-value
PWVa 1.92 1.08 – 3.44 1.62 0.91 – 2.91 0.05
PWVb 2.03 1.10 – 3.74 1.62 0.87 – 3.02 0.04
Bone attenuation/SDa 0.46 0.21 – 1.03 0.33 0.14 – 0.77 0.02
Bone attenuation/SDb 0.43 0.19 – 1.00 0.32 0.13 – 0.76 0.02
FEV1
a 0.82 0.22 – 3.09 0.84 0.21 – 3.29 0.96
FEV1
b 0.80 0.21 – 3.05 0.82 0.21 – 3.25 0.95
15th percentile/SDa 0.80 0.45 – 1.45 0.64 0.45 – 1.63 0.76
15th percentile/SDb 0.80 0.43 – 1.48 0.84 0.43 – 1.64 0.77
Reference category CAC = 0.
aAfter adjustment for age and sex.
bAfter adjustment for age, sex and pack-years of smoking.
CI confidence interval, FEV1 forced expiratory volume in 1 second, PWV pulse wave velocity, SD standard deviation.
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mortality similarly to CAC (Additional file 1). Lower
15th percentile (more emphysema) was associated with
increased all-cause mortality after adjustment for age
and sex (HR 0.65, CI 0.45-0.95, p = 0.03), but not after
adjustment for age, sex, FEV1 and pack-years of smoking
(p = 0.06) (Additional file 2). PWV and bone attenuation
were not associated with all-cause mortality (Additional
file 2).
Discussion
We found that increased CAC was associated with in-
creased arterial stiffness and lower bone attenuation in
COPD subjects, but was not associated with extent of
emphysema. CAC, TAC and extent of emphysema pre-
dicted all-cause mortality in our COPD cohort, while ar-
terial stiffness and bone attenuation were not associated
with all-cause mortality.
In line with previous studies [4,5], our data suggest a
relationship between cardiovascular disease and osteo-
porosis in COPD patients. In our study, the association
between CAC and bone attenuation was independent of
age, sex and pack-years of smoking. In a prospective
study in 2442 postmenopausal women, the associationTable 3 Cox proportional-hazards for all-cause mortality
CAC = 0 0 < CAC≤ 400
Number of subjects 14 41
Mortality, n (%) 1 (7) 4 (10)
CAC - 1.33
CACa - 1.18
CACb - 1.14
CACc - 1.11
aAfter adjustment for age and sex.
bAfter adjustment for age, sex and FEV1.
cAfter adjustment for age, sex, FEV1 and pack-years of smoking.
CAC coronary artery calcium, FEV1 forced expiratory volume in 1 second.between osteoporosis and cardiovascular events was in-
dependent of traditional cardiovascular risk factors such
as age, cigarette smoking, hypertension and hyperli-
pidemia [3]. These data suggest that, in addition to
common risk factors, other factors might be involved
in the vascular-bone relationship, including systemic
inflammation [5], disturbance of the receptor activator
of NF-κB/receptor activator of NF-κB ligand/osteo-
protegerin system or reduced bone perfusion due to
generalised atherosclerosis.
Our data showed a weak association between CAC
and arterial stiffness in a COPD cohort after adjustment
for age, sex and pack-years of smoking. Previous studies
in older populations have found associations between
CAC and arterial stiffness after adjustment for con-
founders [12]. Thus, in addition to common risk factors,
atherosclerosis may cause arterial stiffening [13], while
increased arterial stiffness in turn may promote athero-
sclerotic changes due to greater shear and intraluminal
stresses [14].
In line with previous research [15,16], CAC was not
associated with the degree of airflow obstruction or the
extent of emphysema. CAC was not associated with
the severity of airflow obstruction or the extent ofCAC > 400 Per 10-fold increase in CAC p-value
64 - -
25 (39) - -
6.46 2.17 (1.29 – 3.65) 0.004
5.15 2.02 (1.13 – 3.59) 0.02
5.09 1.94 (1.11 – 3.41) 0.02
4.98 2.01 (1.13 – 3.58) 0.02
Figure 1 Kaplan-Meier, CAC = coronary artery calcium.
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Lung Detection (MILD) study [16], and CAC and prox-
imal aortic calcification were not associated with the se-
verity of airflow obstruction in subjects without clinical
cardiovascular disease of the Multi-Ethnic Study of
Atherosclerosis (MESA) study [15,17]. Notably, as re-
ported previously in this cohort, arterial stiffness did
correlate with the extent of emphysema in COPD
subjects [6]. The relationship between arterial stiffness
and emphysema might be due to connective tissue
degradation [6] or elastin degradation [18].
Bone attenuation was not associated with the extent of
emphysema. In contrast, a recent review stated that
more severe emphysema is associated with reduced bone
mineral density [19]. Bon and colleagues [7] showed that
the extent of emphysema was independently associated
with bone mineral density in 190 current and former
smokers, and Ohara and colleagues [20] demonstrated
that the extent of emphysema was independently associ-
ated with CT measured bone density of the thoracic and
lumbar vertebrae in 65 male COPD subjects. The dis-
crepancy between our data and their data might be due
to differences in the study population (e.g. smokers ver-
sus COPD patients) and methods used (e.g. attenuation
threshold of low attenuation areas).Table 4 Numbers at risk
CAC = 0 0 < CAC≤ 400 CAC > 400
0 months 14 41 64
30 months 13 40 52
60 months 10 31 32
CAC coronary artery calcium.CAC and TAC predicted all-cause mortality after ad-
justment for age, sex, FEV1 and pack-years of smoking.
Several studies have shown that CAC is a predictor of
cardiovascular events and mortality in smokers [21,22].
Here we show that CAC was a strong predictor of all-
cause mortality in a COPD cohort. The hazard ratios re-
ported in our COPD subjects were comparable with
those reported in smokers and subjects without known
coronary artery diseases. In 1159 smokers, the hazard ra-
tio of CAC > 400 was 4.00 (CI 1.17-13.7) for all-cause
mortality compared with CAC ≤ 400 after adjustment for
age, sex, body mass index and history of diabetes or
hypertension [16]. In our study, the hazard ratio of
CAC > 400 was 4.6 (CI 1.63-13.12, p = 0.004) com-
pared with CAC ≤ 400 after adjustment for age, sex,
FEV1 and pack-years of smoking. In 3966 subjects
without known coronary artery diseases, the crude hazard
ratio of CAC ≥ 400 was HR 6.54 (CI 3.51-12.21) for all-
cause mortality [23], and in our study the crude hazard ra-
tio of CAC > 400 was 6.46.
Although CAC and TAC were associated with all-
cause mortality, arterial stiffness was not associated with
all-cause mortality in our COPD cohort. This finding is
in contrast to previous studies that have demonstrated a
relationship between increased arterial stiffness and all-
cause mortality in subjects with chronic kidney disease
[24,25]. The lack of a relationship between increased
arterial stiffness and mortality in our study might be
explained by the fact that we measured carotid-radial
PWV rather than carotid-femoral PWV which is the
gold standard [26]. A study in 305 end-stage renal dis-
ease patients showed indeed that carotid-femoral PWV
was an independent predictor of cardiovascular morta-
lity, whereas carotid-radial and femoral-posterior tibial
PWV were not associated with mortality [27].
In addition, the extent of emphysema was associated
with all-cause mortality after adjustment for age and sex,
but not after adjustment for age, sex and FEV1. As such,
it may be that emphysema causes increased mortality in-
directly through reducing lung function. Our findings
are in line with previous studies that have shown associ-
ations between the extent of emphysema and all-cause
mortality in COPD subjects [28].
Although lower bone attenuation was associated with
increased CAC, bone attenuation was not associated
with all-cause mortality in our COPD cohort. In con-
trast, previous studies have shown that bone density and
rate of bone loss are related to mortality in elderly men
and women [29,30]. The Rotterdam Study demonstrated
that in elderly men the risk of mortality increased when
bone density was below average, and that the relation-
ship between bone density and mortality was nonlinear
[29]. In addition, Szulc and colleagues [30] showed in
781 elderly men that bone resorption markers predicted
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lack of a relationship between bone attenuation and
mortality in our study might be due to the study popula-
tion (e.g. COPD subjects rather than elderly subjects)
and the methods used (e.g. bone attenuation of the tho-
racic vertebrae rather than bone mineral density of the
hip, lumbar spine or whole body).
Our study has several limitations. First, bone attenu-
ation was assessed on low-dose chest CT while dual
energy X-ray absorptiometry is the gold standard. How-
ever, previous data have demonstrated that bone attenu-
ation measured on CT is strongly correlated with bone
mineral density assessed on dual energy X-ray absorpti-
ometry [11]. Second, CAC and TAC were measured on
non-gated scans, however, it has been shown previously
that measurements of CAC and TAC on non-gated
chest CT scans show good agreement with measure-
ments from electrocardiographically gated chest CT scans
[9]. Third, arterial stiffness was measured as carotid-radial
PWV rather than carotid-femoral PWV which is the gold
standard [26]. Although our study has several limitations,
we measured several COPD related manifestations such
as CAC, TAC, bone attenuation and extent of emphysema
in a well-characterised COPD cohort.
Our data showed that CAC, TAC and emphysema
which were measured on low-dose chest CT predicted
all-cause mortality in COPD subjects. We suggest that
low-dose chest CT might contribute to early diagnosis
of COPD related manifestations and improved risk strati-
fication, although further evidence, ideally from rando-
mised controlled trials, are required to determine the
benefits of this screening approach in COPD patients.Conclusions
Our study showed that increased CAC was associated
with increased arterial stiffness and lower bone attenu-
ation in COPD subjects. CAC, TAC and emphysema
predicted all-cause mortality in our COPD cohort, sug-
gesting that quantitative assessment of CAC, TAC and
emphysema on chest CT provides relevant prognostic
information in COPD subjects.Additional files
Additional file 1: Cox proportional-hazards for all-cause mortality.
Additional file 2: Cox proportional-hazards for all-cause mortality.Abbreviations
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